Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Neur-Hitech signs agreement with Xel to develop Alzheimer transdermal patch treatment
April 21st, 2006
Neur-Hitech Pharmaceuticals, Inc. (NHPI) announced that it has signed a development agreement with Xel Herbaceuticals, Inc. to develop a transdermal patch to treat Alzheimer disease. The therapeutic agent is Huperzine A, a molecule currently undergoing U.S. phase II clinical testing as an orally administered treatment for mild-to-moderate Alzheimer disease. Reuben Seltzer, president and CEO of Neur-Hitech, said, "We are very excited by this agreement, especially so because Xel has two world renowned scientist Dr. Dinesh Patel and Dr. Danyi Quan both pioneers in transdermal patch technology, both founders and driving forces behind Xel's transdermal...
Source: Science Letter (2006-04-21)
|
